Champions Oncology (CSBR) Operating Expenses (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Operating Expenses of $14.4 million for Q2 2026, little changed year-over-year from $14.4 million in Q2 2025, and down 14.72% quarter-over-quarter from $16.8 million in Q1 2026.
Champions Oncology (CSBR) Operating Expenses (2010 - 2026) Analysis & Trends
Champions Oncology's Operating Expenses history runs 17 years deep, the most recent figure standing at $14.4 million for Q2 2026.
- In Q2 2026, Operating Expenses changed 0.03% year-over-year to $14.4 million; the TTM figure through Apr 2026 stood at $60.6 million (up 15.6% YoY), while the FY2026 annual figure was $60.6 million, up 15.6% from the prior year.
- Operating Expenses for Q2 2026 stood at $14.4 million, down from $16.8 million in the prior quarter.
- The five-year high for Operating Expenses was $16.8 million in Q1 2026, with the low at $12.4 million in Q1 2022.
- The 5-year median for Operating Expenses is $14.3 million (2022), against an average of $14.2 million.
- The sharpest annual moves came in 2024 and 2026: Operating Expenses decreased 15.75% in 2024, then soared 34.25% in 2026.
- Champions Oncology's Operating Expenses stood at $14.3 million in 2022, then slipped by 5.23% to $13.5 million in 2023, then retreated by 5.7% to $12.8 million in 2024, then increased by 16.41% to $14.8 million in 2025, then decreased by 3.32% to $14.4 million in 2026.
- Business Quant data shows CSBR's Operating Expenses at $14.4 million in Q2 2026, $16.8 million in Q1 2026, and $14.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 14.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 14.36 Mn |
| Jan 31, 2026 | 16.84 Mn |
| Oct 31, 2025 | 14.85 Mn |
| Jul 31, 2025 | 14.52 Mn |
| Apr 30, 2025 | 14.36 Mn |
| Jan 31, 2025 | 12.54 Mn |
| Oct 31, 2024 | 12.76 Mn |
| Jul 31, 2024 | 12.73 Mn |
| Apr 30, 2024 | 14.27 Mn |
| Jan 31, 2024 | 14.60 Mn |
| Oct 31, 2023 | 13.53 Mn |
| Jul 31, 2023 | 15.11 Mn |
| Apr 30, 2023 | 15.59 Mn |
| Jan 31, 2023 | 15.23 Mn |
| Oct 31, 2022 | 14.27 Mn |
| Jul 31, 2022 | 14.03 Mn |
| Apr 30, 2022 | 13.19 Mn |
| Jan 31, 2022 | 12.36 Mn |
| Oct 31, 2021 | 11.52 Mn |
| Jul 31, 2021 | 11.43 Mn |